Denis Lacombe is the Chief Executive Officer of the European Organisation for Research and Treatment of Cancer (EORTC), leading Europe’s largest independent academic cancer clinical trials network. During his leadership era, EORTC has consolidated its role as a central infrastructure for multinational, investigator-initiated cancer trials, coordinating studies across hundreds of centres across many countries and generating data that directly informs clinical practice and regulatory decision-making in Europe.
Under Lacombe’s leadership, EORTC has delivered several structural and scientific advances. These include the expansion of SPECTA, EORTC’s molecular screening and translational research platform, enabling biomarker-driven and precision-oncology trials at scale; the strengthening of EORTC’s Quality of Life Group, whose patient-reported outcome instruments are now embedded in trials worldwide; and the modernisation of EORTC’s clinical trial operations to support complex, adaptive, and regulatory-grade studies. He has also overseen deeper engagement with European regulators, cancer policy bodies, and international partners, positioning EORTC as a key contributor to pan-European cancer research strategy while preserving its independence from commercial influence.
Dr. Lacombe began his career in oncology drug development in the pharmaceutical industry before joining EORTC in 1993 as a research fellow. He advanced through roles including Clinical Research Physician, Director of EORTC Headquarters in 2010, Director General in 2015, and CEO in 2021. He has authored over 100 peer-reviewed publications and has contributed to the strategic evolution of EORTC’s pan-European research infrastructure and stakeholder partnerships.
The 100 CEOs featured here reflect the diversity and complexity of modern oncology leadership. In 2025, some lead the world’s largest cancer institutions; others guide specialized societies or emerging innovators. What unites them is responsibility: for millions of patients, for the integrity of science, and for the future direction of cancer care globally.
This list is not a celebration of power, but a recognition of stewardship, accountability, and impact – and of the leaders whose choices continue to shape the fight against cancer. For the many deserving individuals not mentioned in this list, we will continue to acknowledge, honor and elevate your voices in our daily publications from across the world.
See the full list of The 100 Influential CEOs in Oncology in 2025 and stay tuned for other special category nominations.
